Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
Rhea-AI Summary
Sonoma Pharmaceuticals (Nasdaq:SNOA) reported strong revenue growth for Q4 and fiscal 2026 while narrowing losses. Q4 2026 revenue rose 48% to $5.6M; FY 2026 revenue grew 37% to $19.5M. Net and EBITDA losses improved, though the company remains unprofitable.
United States sales drove growth, with Q4 revenue up 194% and FY revenue up 117%. Gross margin held at 38–39%. Operating costs increased on inflation-driven salary growth. Sonoma highlighted new U.S. partnerships, FDA MoCRA registration for a facial spray, and dermatology product recognitions.
Positive
- Q4 2026 revenue up 48% to $5.6M
- FY 2026 revenue up 37% to $19.5M
- United States Q4 revenue up 194% to $2.0M
- United States FY 2026 revenue up 117%
- Q4 2026 EBITDA loss reduced 66% to $0.2M
- FY 2026 EBITDA loss reduced 38% to $2.1M
- FY 2026 gross profit increased to $7.4M at 38% margin
- Cash and equivalents of $2.4M at March 31, 2026
Negative
- Company remains loss-making with FY 2026 net loss of $3.2M
- Q4 2026 gross margin slipped to 39% from 41% year-over-year
- Q4 2026 operating expenses up 16% to $2.5M
- FY 2026 operating expenses up 8% to $9.9M
- Revenue declines in Asia and Latin America from Q4 order timing
- Latin America revenue decreased for FY 2026 on order timing
News Market Reaction – SNOA
In the Jun 17 session, SNOA gained 4.55%, reflecting a moderate positive market reaction. Argus tracked a peak move of +12.0% during that session. Argus tracked a trough of -11.0% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 4.2x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Q3 2026 earnings | Positive | +1.4% | Q3 and nine‑month revenue up with better gross margin and smaller EBITDA loss. |
| Nov 04 | Q2 2026 earnings | Positive | -0.5% | Record Q2 revenue with strong U.S. growth and improved EBITDA but small share pullback. |
| Aug 07 | Q1 2026 earnings | Positive | -1.6% | Q1 revenue up 18% and robust U.S. growth despite ongoing net loss and margin dip. |
| Jun 17 | FY/Q4 2025 results | Positive | -3.4% | FY2025 revenue and margins improved with lower losses and tighter operating costs. |
| Feb 05 | Q3 2025 earnings | Positive | -0.4% | Q3 2025 revenue grew double digits with positive operating cash flow but lower margins. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases often showed positive fundamentals but modestly negative next-day moves, indicating a tendency for the stock to fade good financial news.
Over the past five earnings cycles, Sonoma reported consistent revenue growth and gradual loss reduction. Q1–Q3 FY2026 updates highlighted rising U.S. sales, expanding retail partnerships, and stable gross margins near 36–38%. FY2025 results already showed improving EBITDA and reduced net loss. Despite these positives, four of five earnings events saw negative 24-hour price reactions, suggesting investors frequently sold into strength or focused on ongoing losses and capital needs even as operations improved.
Key Terms
ebitda financial
hypochlorous acid medical
hocl medical
modernization of cosmetics regulation act of 2022 regulatory
mocra regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Revenues increased
48% in Q4 2026 compared to Q4 2025, and37% in FY 2026 compared to FY 2025
United States revenues increased
194% in Q4 2026 compared to Q4 2025 and117% in FY 2026 compared to FY 2025
Net loss improved
25% in Q4 2026 compared to Q4 2025, and8% in FY 2026 compared to FY 2025
EBITDA loss improved
66% in Q4 2026 compared to Q4 2025, and38% in FY 2026 compared to FY 2025
BOULDER, CO / ACCESS Newswire / June 16, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2026 and the fourth quarter ended March 31, 2026.
"Fiscal 2026 was a year of significant progress for Sonoma," remarked Amy Trombly, CEO of Sonoma. "We delivered strong revenue growth while continuing to improve the financial health of the business as we maintained our focus on strategic growth, operational discipline, cost management, and efficient execution. Throughout the year, we continued to expand commercial partnerships, advance regulatory initiatives, and invest in product innovation. As we look ahead, our priority remains building a stronger and more scalable business by focusing on opportunities that align with our strategic objectives, generate attractive returns, and support long-term shareholder value. We believe the growing adoption of hypochlorous acid across healthcare, consumer, and wellness markets continues to create meaningful opportunities for Sonoma, and we remain focused on translating those opportunities into sustainable growth and improved profitability."
Recent Business Highlights
Sonoma continued to expand its product offerings, grow its distribution network, and expand regulatory approvals for its products:
In October 2025, Sonoma announced the registration of its manufacturing facility and listing of its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
Also in October 2025, Sonoma announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP, to be distributed into hospital systems, home healthcare and other healthcare channels across the United States.
In August 2025, Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel earned the National Psoriasis Foundation (NPF) Seal of Recognition, and in November 2025, Reliefacyn earned the National Rosacea Society (NRS) Seal of Acceptance.
Results for the Quarter Ended March 31, 2026
Total revenue of
During the fourth quarter of fiscal year 2026, Sonoma reported total revenues of
Total operating expenses during the fourth quarter of fiscal year 2026 were
Net loss for the fourth quarter of fiscal year 2026 was
As of March 31, 2026, Sonoma had cash and cash equivalents of
Results for the Year Ended March 31, 2026
Total revenues for fiscal year 2026 of
For fiscal year 2026, Sonoma reported total revenues of
Total operating expenses during fiscal year 2026 were
Net loss during fiscal year 2026 was
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The company's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact businessdevelopment@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn® and Reliefacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
March 31, | ||||||||
2026 | 2025 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 2,399 | $ | 5,374 | ||||
Accounts receivable, net | 2,527 | 2,232 | ||||||
Inventories, net | 3,651 | 2,915 | ||||||
Prepaid expenses and other current assets | 3,436 | 1,915 | ||||||
Current portion of deferred consideration, net of discount | 87 | 212 | ||||||
Total current assets | 12,100 | 12,648 | ||||||
Property and equipment, net | 310 | 225 | ||||||
Operating lease, right of use assets | 602 | 84 | ||||||
Deferred tax asset, net | 884 | 589 | ||||||
Deferred consideration, net of discount, less current portion | - | 73 | ||||||
Other assets | 64 | 74 | ||||||
Total assets | $ | 13,960 | $ | 13,693 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,923 | $ | 953 | ||||
Accrued expenses and other current liabilities | 2,252 | 2,224 | ||||||
Deferred revenue, current portion | 284 | 641 | ||||||
Short-term debt | 222 | 220 | ||||||
Operating lease liabilities, current portion | 151 | 58 | ||||||
Total current liabilities | 4,832 | 4,096 | ||||||
Deferred revenue, net of current portion | - | 17 | ||||||
Withholding tax payable | 5,564 | 5,142 | ||||||
Operating lease liabilities, less current portion | 469 | 27 | ||||||
Total liabilities | 10,865 | 9,282 | ||||||
Commitments and Contingencies | ||||||||
Stockholders' Equity: | ||||||||
Convertible preferred stock, | - | - | ||||||
Common stock, | - | - | ||||||
Additional paid-in capital | 207,319 | 206,593 | ||||||
Accumulated deficit | (200,981 | ) | (197,806 | ) | ||||
Accumulated other comprehensive loss | (3,243 | ) | (4,376 | ) | ||||
Total stockholders' equity | 3,095 | 4,411 | ||||||
Total liabilities and stockholders' equity | $ | 13,960 | $ | 13,693 | ||||
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share amounts)
Three Months Ended March 31, | Year Ended March 31, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
(Unaudited) | ||||||||||||||||
Revenues | $ | 5,561 | $ | 3,754 | $ | 19,529 | $ | 14,288 | ||||||||
Cost of revenues | 3,380 | 2,226 | 12,114 | 8,823 | ||||||||||||
Gross profit | 2,181 | 1,528 | 7,415 | 5,465 | ||||||||||||
Operating expenses | ||||||||||||||||
Research and development | 545 | 411 | 2,271 | 1,814 | ||||||||||||
Selling, general and administrative | 1,987 | 1,773 | 7,605 | 7,361 | ||||||||||||
Total operating expenses | 2,532 | 2,184 | 9,876 | 9,175 | ||||||||||||
Loss from operations | (351 | ) | (656 | ) | (2,461 | ) | (3,710 | ) | ||||||||
Other (expense) income | (146 | ) | 128 | (958 | ) | 803 | ||||||||||
Loss before income taxes | (497 | ) | (528 | ) | (3,419 | ) | (2,907 | ) | ||||||||
Income tax benefit (expense) | (84 | ) | (248 | ) | 244 | (550 | ) | |||||||||
Net loss | $ | (581 | ) | $ | (776 | ) | $ | (3,175 | ) | $ | (3,457 | ) | ||||
Net loss per share: basic and diluted | $ | (0.33 | ) | $ | (0.48 | ) | $ | (1.89 | ) | $ | (2.79 | ) | ||||
Weighted-average number of shares: basic and diluted | 1,736 | 1,619 | 1,684 | 1,241 | ||||||||||||
Other comprehensive loss | ||||||||||||||||
Net loss | $ | (581 | ) | $ | (776 | ) | $ | (3,175 | ) | $ | (3,457 | ) | ||||
Foreign currency translation adjustments | (52 | ) | 178 | 1,133 | (1,653 | ) | ||||||||||
Comprehensive loss | $ | (633 | ) | $ | (598 | ) | $ | (2,042 | ) | $ | (5,110 | ) | ||||
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited)
Three Months Ended March 31, | Year Ended March 31, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
(1) Loss from operations minus non-cash expenses EBITDA loss: | ||||||||||||||||
GAAP loss from operations as reported | $ | (351 | ) | $ | (656 | ) | $ | (2,461 | ) | $ | (3,710 | ) | ||||
Non-cash adjustments: | ||||||||||||||||
Stock-based compensation | 134 | 90 | 255 | 224 | ||||||||||||
Depreciation and amortization | 34 | 31 | 139 | 138 | ||||||||||||
Non-GAAP loss from operations minus non-cash expenses EBITDA loss | $ | (183 | ) | $ | (535 | ) | $ | (2,067 | ) | $ | (3,348 | ) | ||||
(2) Net loss minus non-cash and one-time expenses: | ||||||||||||||||
GAAP net loss as reported | $ | (581 | ) | $ | (776 | ) | $ | (3,175 | ) | $ | (3,457 | ) | ||||
Non-cash adjustments: | ||||||||||||||||
Stock-based compensation | 134 | 90 | 255 | 224 | ||||||||||||
Non-cash foreign exchange transaction losses (gains) | 169 | 162 | 1,446 | (243 | ) | |||||||||||
Income tax expense (benefit) | 84 | 248 | (244 | ) | 550 | |||||||||||
Depreciation and amortization | 34 | 31 | 139 | 138 | ||||||||||||
Non-GAAP net loss minus non-cash expenses | $ | (160 | ) | $ | (245 | ) | $ | (1,579 | ) | $ | (2,788 | ) | ||||
(3) Operating expenses minus non-cash expenses | ||||||||||||||||
GAAP operating expenses as reported | $ | 2,532 | $ | 2,184 | $ | 9,876 | $ | 9,175 | ||||||||
Non-cash adjustments: | ||||||||||||||||
Stock-based compensation | (134 | ) | (90 | ) | (255 | ) | (224 | ) | ||||||||
Depreciation and amortization | (34 | ) | (31 | ) | (139 | ) | (138 | ) | ||||||||
Non-GAAP operating expenses minus non-cash expenses | $ | 2,364 | $ | 2,063 | $ | 9,482 | $ | 8,813 | ||||||||
(1) | Loss from operations minus non-cash expenses (EBITDA) is a non-GAAP financial measure. The Company defines operating loss minus non-cash expenses as GAAP reported operating loss minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period. . Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. |
(2) | Net loss minus non-cash and one-time expenses is a non-GAAP financial measure. The company defines net loss minus non-cash expenses as GAAP reported net loss minus depreciation and amortization, stock-based compensation, income taxes, and non-cash foreign exchange transaction losses. The company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. |
(3) | Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. . Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
REVENUE SCHEDULES
(In thousands)
The following table shows the Company's revenues by geographic region:
Three Months Ended March 31, | ||||||||||||||||
2026 | 2025 | $ Change | % Change | |||||||||||||
(Unaudited) | ||||||||||||||||
United States | $ | 2,002 | $ | 681 | $ | 1,321 | 194 | % | ||||||||
Europe | 1,725 | 1,580 | 145 | 9 | % | |||||||||||
Asia | 381 | 485 | (104 | ) | (21 | %) | ||||||||||
Latin America | 759 | 788 | (29 | ) | (4 | %) | ||||||||||
Rest of the World | 694 | 220 | 474 | 215 | % | |||||||||||
Total | $ | 5,561 | $ | 3,754 | $ | 1,807 | 48 | % | ||||||||
Year Ended March 31, | ||||||||||||||||
2026 | 2025 | $ Change | % Change | |||||||||||||
United States | $ | 5,674 | $ | 2,611 | $ | 3,063 | 117 | % | ||||||||
Europe | 6,904 | 5,523 | 1,381 | 25 | % | |||||||||||
Asia | 2,900 | 2,317 | 583 | 25 | % | |||||||||||
Latin America | 2,373 | 2,962 | (589 | ) | (20 | %) | ||||||||||
Rest of the World | 1,678 | 875 | 803 | 92 | % | |||||||||||
Total | $ | 19,529 | $ | 14,288 | $ | 5,241 | 37 | % | ||||||||
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire